LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Начало・Списък с акции・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Затворен

СекторЗдравеопазване

15.07 -0.4

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.01

Максимум

15.12

Ключови измерители
By Trading Economics
Приходи	222M 227M
Продажби	-23M 139M
P/E Средно за сектора	5.693 105.69
Марж на печалбата	163.843
Служители	1,780
EBITDA	6.3M 1.3M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+27.67% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-49M 2.7B
Предишно отваряне	15.47
Предишно затваряне	15.07

Настроения в новините

By Acuity

50%

160 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

14.24 / 14.78 Подкрепа & съпротива

Hutchison China MediTech Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.11.2025 г., 17:45 ч. UTC

Печалби

Значими двигатели на пазара

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14.11.2025 г., 17:31 ч. UTC

Печалби

Значими двигатели на пазара

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

15.11.2025 г., 18:03 ч. UTC

Печалби

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

15.11.2025 г., 15:43 ч. UTC

Печалби

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

15.11.2025 г., 12:00 ч. UTC

Печалби

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

15.11.2025 г., 09:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

15.11.2025 г., 09:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

15.11.2025 г., 00:08 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14.11.2025 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14.11.2025 г., 23:02 ч. UTC

Пазарно говорене

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14.11.2025 г., 22:35 ч. UTC

Печалби

Придобивния, сливания и поглъщания

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14.11.2025 г., 22:32 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14.11.2025 г., 22:29 ч. UTC

Печалби

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14.11.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

14.11.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14.11.2025 г., 20:27 ч. UTC

Пазарно говорене

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14.11.2025 г., 20:23 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14.11.2025 г., 20:17 ч. UTC

Придобивния, сливания и поглъщания

Several State Attorneys General Oppose Railroad Merger -- WSJ

14.11.2025 г., 19:29 ч. UTC

Пазарно говорене

Печалби

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14.11.2025 г., 18:44 ч. UTC

Пазарно говорене

Печалби

Disney's Growth Now Hinges More on ESPN -- Market Talk

14.11.2025 г., 18:27 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.11.2025 г., 18:27 ч. UTC

Пазарно говорене

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14.11.2025 г., 18:20 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

14.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

14.11.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

14.11.2025 г., 16:51 ч. UTC

Пазарно говорене

Starbucks Gets Holiday Sales Lift -- Market Talk

14.11.2025 г., 16:48 ч. UTC

Пазарно говорене

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14.11.2025 г., 16:38 ч. UTC

Пазарно говорене

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Hutchison China MediTech Ltd ADR Прогноза

Ценова цел

By TipRanks

27.67% нагоре

12-месечна прогноза

Среден 19.38 USD 27.67%

Висок 25 USD

Нисък 13.75 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Hutchison China MediTech Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Hutchison China MediTech Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

14.24 / 14.78Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

160 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.